Inhibikase Therapeutics IKT
NASDAQ IKT
$2.50 -0.02 (-0.79%)
As of: Sep 4, 2026 · 3:59 PM EDT

Inhibikase Therapeutics (IKT) Property, Plant & Equipment (Net) (2022 - 2025)

Analysis

Inhibikase Therapeutics (IKT) Property, Plant & Equipment (Net) (2022 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Property, Plant & Equipment (Net) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.67 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 5.46 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.96 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 2.06 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 34.61 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.64 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 554.14 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 107.22 Mn
10 Inhibikase Therapeutics 435.56 Mn 276.54 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 23,687.00
Mar 31, 2025 47,845.00
Dec 31, 2024 47,100.00
Sep 30, 2024 53,667.00
Jun 30, 2024 60,235.00
Mar 31, 2024 66,804.00
Dec 31, 2023 73,372.00
Sep 30, 2023 79,940.00
Jun 30, 2023 86,523.00
Mar 31, 2023 231,489.00
Dec 31, 2022 236,532.00
Sep 30, 2022 241,574.00
Jun 30, 2022 43,089.00